Skip to content

Pulsed Dye Laser for the Psoriatic Nail

Pulsed Dye Laser for the Psoriatic Nail

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01303185
Enrollment
25
Registered
2011-02-24
Start date
2011-01-31
Completion date
2012-02-29
Last updated
2014-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Nail

Keywords

Psoriatic Nail, Pulsed dye laser

Brief summary

The treatment options for nail psoriasis have been limited, and the management of nail psoriasis has been challenging for physicians.To evaluate the effect of pulsed dye laser (PDL) in the treatment of nail psoriasis.

Detailed description

Psoriatic nails of patient's right hand were treated using PDL (595 nm) .The pulsed duration is 1.5ms, the beam diameter is 7mm, and the laser energy is 8.0 to 10.0 J/cm2. The treatment course of pulse dye laser is once monthly for 6 months. Psoriatic nails of both hands are treated with Tazarotene cream for 6 months. Clinical efficacy is statistically evaluated according to Nail Psoriasis Severity Index (NAPSI) score differences between right and left hand one month after 3rd and 6th therapy.

Interventions

None listed

Sponsors

Taipei Medical University WanFang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Psoriatic nail refractory to other topical and systemic treatment therapy * ≧ 16 years old

Exclusion criteria

* Patient with pregnancy * Patient with photo sensitivity * Patient with severe wound around finger nails or paronychia * Patient with hypersensitivity to Tazarotene cream

Design outcomes

Primary

MeasureTime frame
NAPSI3rd and 6th months
global physician assessment3rd and 6th months

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026